Eli Lilly & Co. (LLY)

109.70
1.80 1.67
NYSE : Health Technology
Prev Close 107.90
Open 108.35
Day Low/High 108.22 / 110.10
52 Wk Low/High 104.17 / 132.13
Volume 1.76M
Avg Volume 3.54M
Exchange NYSE
Shares Outstanding 965.43M
Market Cap 104.61B
EPS 3.10
P/E Ratio 25.74
Div & Yield 2.58 (2.34%)

My Takeaways and Observations

I wrote in my 15 Surprises for 2017 that Mr. Market may make a yearly high in the first two weeks of January. We are now wrapping up that period -- and I plan to expand my relatively small short exposure.   In other words, I am sticking to my script...

3 Takeover Candidates in the Drug Space

3 Takeover Candidates in the Drug Space

Potential acquirers include Gilead Sciences, Johnson & Johnson, Pfizer, Merck and Novartis.

3 Takeover Candidates in the Drug Space

3 Takeover Candidates in the Drug Space

Potential acquirers include Gilead Sciences, Johnson & Johnson, Pfizer, Merck and Novartis.

Eli Lilly upgraded at Morgan Stanley

My Takeaways and Observations

Slow day, at meetings all morning.   Despite the strength in our currency (and its adverse implications on multi-national profitability), there was no follow-through to yesterday's schmeissing.   I reflected on my July call that we have hit a Genera...

Inside Eli Lilly's Surging Stock Price

Inside Eli Lilly's Surging Stock Price

For the first time in three years, Eli Lilly's guidance for next year has topped Wall Street's consensus estimates.

Eli Lilly Surges After 2017 Guidance Beats Street Forecast

Eli Lilly Surges After 2017 Guidance Beats Street Forecast

Eli Lilly shares are up after the drugmaker offered 2017 earnings guidance above Wall Street's forecast.

Eli Lilly Teams With Express Scripts to Offer Discounted Insulin

Eli Lilly Teams With Express Scripts to Offer Discounted Insulin

Shares of Eli Lilly were higher Tuesday after announcing that starting January of 2017, customers will be able to purchase insulin at a discount of up to 40%.

Biogen Shares Up Following Eli Lilly's Failed Alzheimer's Study

Biogen Shares Up Following Eli Lilly's Failed Alzheimer's Study

Shares of Biogen soared Friday after the biotech company's early clinical trial data of its experimental Alzheimer's drug was leaked and Eli Lilly's study failed.

My Takeaways and Observations

What a strange day -- maybe even ominous.   This table tells it all.    The divergences I have been mentioning this week intensified today, with the technology-laden Nasdaq taken out to the shed and the Russell 2000 Index trading lower for the third...

My Takeaways and Observations (3:30 p.m. Edition)

It may be time to embrace the contrary.    First issue (!!): The Palm Beach Chronicles.   My weekly (brief) technical review of the markets -- cooling off ahead?    BTIG's Stockton is bullish and so, as I have expressed, are most others!   Campbell ...

Allergan Could Pay $1 Billion for Chase Pharma

Allergan Could Pay $1 Billion for Chase Pharma

'Milestone payments' could boost deal's $125 million announced price.

Biotech Hits an Inflection Point

Biotech Hits an Inflection Point

The worst appears to be over for this sector; we could see big growth ahead.

The Good, the Bad and the Ugly

"If you work for a living, why the hell do you kill yourself working?" -- Tuco the Ugly" The Good, the Bad and the Ugly" I further added to my short exposure today in a quiet, pre-Thanksgiving trading session. And now it's time to run down "The Good...

On the Hunt for Holiday Movers

On the Hunt for Holiday Movers

I'm still bullish, but I'm looking over my shoulder to see if there are some bears sneaking up.

Cramer: Just When You Thought It Was Too Late to Get In … It Isn't

Cramer: Just When You Thought It Was Too Late to Get In … It Isn't

These 'wing and a prayer' stocks are full of surprises.

Eli Lilly: Is There Life After a Big Gap to the Downside?

Eli Lilly: Is There Life After a Big Gap to the Downside?

It will likely take several months of base building before LLY looks better on the charts.

Stocks Retreat From Record Highs; Deere Shares Surge on Earnings

Stocks Retreat From Record Highs; Deere Shares Surge on Earnings

U.S. stocks pulled back Wednesday, from their record highs on Tuesday, when the Dow Jones Industrial Average crossed 19,000 and the S&P 500 topped 2,200.

A Tale of Two Stocks

Here are two extremes. Eli Lilly down nearly $12, or more than 15%, in pre-market trading on the failure of Solanezumab to meet its primary endpoint. And Deere up $9, or more than 10%, in the pre-market on a giant earnings beat.

Cramer: Trump Rally is a FANG + FANG Affair

Cramer: Trump Rally is a FANG + FANG Affair

Today high-growth tech and natural resources stocks are both going higher without sending much lower at all.

Cramer: Don't Just Stand There Like Bambi; Sell Some

Cramer: Don't Just Stand There Like Bambi; Sell Some

Stocks in the health care sector seem to have no underpinnings whatsoever.

Cramer: Credibility Is a Precious Market Commodity

Cramer: Credibility Is a Precious Market Commodity

And if it's lost, good luck getting it back.

Cramer: How Bad Was Today? Let Us Count the Ways

Cramer: How Bad Was Today? Let Us Count the Ways

Today there was a virtual vacuum of good news in the stock market.

Jim Cramer Says Pricing Pressure is the Reason Not to Buy Valeant

Jim Cramer Says Pricing Pressure is the Reason Not to Buy Valeant

Jim Cramer says there are other reasons not to buy Valeant, other than the criminal investigation.

Eli Lilly Has a Dominant Trend: Down

Eli Lilly Has a Dominant Trend: Down

A chart buyer will actually wait for the trend to turn before buying.

Eli Lilly numbers reduced at Leerink

Scanning the Earnings Universe, Plus Overnight Tidbits

Thus far I am seeing a mixed picture of earnings reports this morning and last night. Visa guided a bit lower on a more costly Visa Europe integration, Whirlpool misses and cuts guidance, and Lilly results were well below on both earnings per share ...

Pivotal Research Is Not Chickening Out

Pivotal Research Is Not Chickening Out

A class-action lawsuit over poultry pricing could result in substantial damages for Tyson Foods, analyst says.

Chi-Med Not Your Typical 'Binary Biotech' Says CEO

Chi-Med Not Your Typical 'Binary Biotech' Says CEO

Chi-Med may be pressing ahead with a series of late-stage oncology drug trials, but it is anything but a one-trick pony biotech company.

Eli Lilly upgraded at Goldman